CSPC Pharmaceutical Group Ltd
CVG
Company Profile
Business description
CSPC Pharmaceutical Group listed on the Hong Kong Stock Exchange in 1994 and is one of the largest pharmaceutical companies in China. Its biggest business segment is the finished drugs segment which accounts for nearly 80% of its total revenue. Now it has a diversified pipeline portfolio in seven therapeutic areas including nervous system diseases, oncology, anti-infective to cardiovascular disease, respiratory system disease, and metabolism. CSPC also has a bulk drug product segment including vitamin C, antibiotics, and a caffeine series.
Contact
No. 226 Huanghe Street
Hebei Province
Shijiazhuang050035
CHNT: +86 31187037015
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
20,300
Stocks News & Analysis
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,456.80 | 15.00 | -0.18% |
| CAC 40 | 7,427.12 | 3.45 | 0.05% |
| DAX 40 | 20,363.91 | 92.58 | 0.46% |
| Dow JONES (US) | 42,518.28 | 221.16 | 0.52% |
| FTSE 100 | 8,258.71 | 57.17 | 0.70% |
| HKSE | 19,286.07 | 66.29 | 0.34% |
| NASDAQ | 19,044.39 | 43.71 | -0.23% |
| Nikkei 225 | 38,444.58 | 29.72 | -0.08% |
| NZX 50 Index | 12,943.57 | 59.19 | 0.46% |
| S&P 500 | 5,842.91 | 6.69 | 0.11% |
| S&P/ASX 200 | 8,213.30 | 17.70 | -0.22% |
| SSE Composite Index | 3,227.12 | 13.82 | -0.43% |